<DOC>
	<DOCNO>NCT00363311</DOCNO>
	<brief_summary>The purpose study examine effect dutasteride inhibition low-risk , localized prostate cancer progression men would otherwise receive active therapy ( expectant management ) .</brief_summary>
	<brief_title>Assessment Of Dutasteride ( AVODART ) In Extending The Time To Progression Of Low-Risk , Localized Prostate Cancer In Men</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<criteria>Inclusion criterion : Must male ≥48 ≤82 year age Have biopsy proven , lowrisk , localized prostate cancer active expectant management 14 month . [ For purpose assess subject eligibility diagnostic biopsy must include least 10 core , ( &lt; 4 core positive &lt; 50 % one core positive ) must obtain within 8 month screen ] . If saturation biopsy perform ( 20 core obtain ) 23 core positive prostate cancer &lt; 50 % one core positive . Initial diagnosis T1a/T1b obtain Transrectal ultrasound ( TURP ) allow . Gleason score ≤6 [ Gleason pattern 4 must present biopsy ( initial entry ) ] Clinical stage T1cT2a Serum Prostate Specific Antigen ( PSA ) ≤11ng/mL . If screen PSA value central laboratory great 11ng/ml , one PSA retest allow central laboratory A life expectancy great five year . Able swallow retain oral medication Able willing participate full 3 year study Able read write ( health outcome questionnaire selfadministered ) , understand instruction relate study procedure give write informed consent . Exclusion criterion : Subject ever treat prostate cancer follow : Radiotherapy ( external beam brachytherapy ) Chemotherapy Hormonal therapy ( e.g. , megestrol , medroxyprogesterone , cyproterone , diethylstilbestrol ( DES ) Oral glucocorticoid Gonadotropinreleasing hormone ( GnRH ) analogue ( e.g. , leuprolide , goserelin ) Glucocorticoids , except inhaled topical , permit within 3 month prior visit one Current and/or previous use follow medication : Finasteride ( Proscar , Propecia ) , Dutasteride ( GI198745 , AVODART ) exposure within 6 month prior study entry exclude . Any investigational 5αreductase inhibitor within past 12 month . Anabolic steroid ( subject must discontinue 6 month prior study entry eligible ) Drugs antiandrogenic property within past 6 month ( e.g , . spironolactone , flutamide , bicalutamide , *cimetidine , *ketoconazole , metronidazole , progestational agent ) NOTE : Use dietary herbal supplement ( e.g. , selenium , Vitamin E , saw palmetto ) study discourage prohibit . All dietary herbal supplement usage record case report form ( CRF ) . *The use cimetidine permit prior study entry . The use topical ketoconazole permit prior study . Prostate volume &gt; 80 cc Subject prior prostatic surgery include Transurethral needle ablation prostate ( TUNA ) , TURP , Transurethral incision prostate ( TUIP ) , laser treatment , thermotherapy , balloon dilatation , prosthesis , ultrasound ablation within 3 month enrolment Severe Benign Prostatic Hyperplasia ( BPH ) symptom manifest International Prostate Symptom Score ( IPSS ) symptom score ( calculate use first 7 question ) ≥25 &gt; 20 already alpha blocker therapy . Participation investigational market drug trial within 30 day prior first dose study drug anytime study period . Any unstable serious coexist medical condition ( ) include limited myocardial infarction , coronary bypass surgery , unstable angina , cardiac arrhythmia , clinically evident congestive heart failure , cerebrovascular accident within 6 month prior Screening visit ; uncontrolled diabetes peptic ulcer disease uncontrolled medical management . Abnormal liver function test ( great 2 time upper limit normal alanine aminotransferase [ ALT ] , aspartate aminotransferase [ AST ] , alkaline phosphatase [ ALP ] ) ; bilirubin &gt; 1.5 time upper limit normal . Serum creatinine &gt; 1.5 time upper limit normal . History another malignancy within five year could affect diagnosis prostate cancer . History current evidence drug alcohol abuse within last 12 month . History illness ( include psychiatric ) , opinion investigator , might confound result study pose additional risk subject . Known hypersensitivity 5αreductase inhibitor drug chemically related dutasteride .</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Dutasteride Prostate Cancer Expectant management REDEEM</keyword>
</DOC>